Literature DB >> 32592406

Immune response in children with COVID-19 is characterized by lower levels of T-cell activation than infected adults.

Daniele Moratto1, Mauro Giacomelli2, Marco Chiarini1, Lucia Savarè2, Barbara Saccani3, Mario Motta4, Silviana Timpano5, Piercarlo Poli5, Simone Paghera6, Luisa Imberti6, Stefania Cannizzo7, Eugenia Quiros-Roldan3, Giulia Marchetti7, Raffaele Badolato2,5.   

Abstract

Study of immunological features of immune response in 14 children (aged from 12 days up to 15 years) and of 10 adults who developed COVID-19 show increased number of activated CD4 and CD8 cells expressing DR and higher plasmatic levels of IL-12 and IL-1β in adults with COVID-19, but not in children. In addition, plasmatic levels of CCL5/RANTES are higher in children and adults with COVID-19, while CXCL9/MIG was only increased in adults. Higher number of activated T cells and expression of IL-12 and CXCL9 suggest prominent Th1 polarization of immune response against SARS-CoV2 in infected adults as compared with children.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CCL5/RANTES; COVID-19; CXCL9/MIG; SARS-CoV-2; T-cell activation

Mesh:

Substances:

Year:  2020        PMID: 32592406      PMCID: PMC7361574          DOI: 10.1002/eji.202048724

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   6.688


To the Editor COVID‐19 [1, 2] has broad spectrum of manifestations, ranging from mild respiratory illness to severe pneumonia resulting in multiorgan failure and death in adult population. In children, the disease has a mild course characterized by fever, cough, and diarrhea [2, 3, 4]. In addition, the infection can often be asymptomatic in infants in their first year of life despite respiratory diseases such as cystic fibrosis [5, 6]. Despite the large number of children infected by SARS‐Cov‐2, little is known about their immune response. We describe 14 children (P1 to P9; age from 12 days to 15 years) who have been infected during the SARS‐Cov‐2 epidemics and have developed from mild to moderate clinical manifestations (Supporting information Table 1). In order to evaluate the inflammatory response during SARS‐Cov‐2 infection, we measured the levels of chemokines, or cytokines which are produced during viral or bacterial infection and are important in the innate immune response [7]. CXCL10/IP10, CXCL9/MIG, CCL5/RANTES CCL2/MCP‐1, and IL‐8 (CXCL8/IL‐8) were measured on plasma of 14 children and 9 adults with COVID‐19 (Supporting information Table 1). We observed that levels of plasmatic CCL5/RANTES were significantly higher in both children and adults with COVID‐19 as compared to control subjects (Fig. 1). While CXCL9/MIG was higher in adults with COVID‐19 in comparison with control group (Fig. 1). CXCL10/IP10, CCL2‐MCP1, and CXCL8/IL‐8 (data not shown) were detected at comparable levels in the three groups of subjects (Fig. 1).
Figure 1

Chemokines and cytokines evaluation in children and adults affected by COVID‐19. Plasmatic levels of CXCL10/IP10, CXCL9/MIG, CCL5/RANTES, and CCL2/MCP‐1 in 14 children, 10 adults with COVID‐19 were measured by Bead Array flow cytometry assay on a single plasma sample at the time of hospital admission, and 10 children with other infections are shown as median ± semi‐interquartile range (pg/ml). Kruskal–Wallis comparison test was used to compare values between healthy control subjects, COVID‐19 children, and adults for analysis of CXCL10/IP10 (NS), CXCL9/MIG (p = 0.0055), CCL5/RANTES (p = 0.0047), and CCL2/MCP‐1 (NS). When the test was statistically significant between three groups, Dunn's multiple comparison test was used for pairwise differences between control group and COVID‐19 children or adults. This was analysis showed significant difference in CXCL9 levels in between COVID‐19 adults and control subjects (p < 0.05), in CCL5 levels between COVID‐19 adults and control subjects (p < 0.05) and between COVID‐19 and control subjects. Nonsignificant (NS) when p > 0.05.

Chemokines and cytokines evaluation in children and adults affected by COVID‐19. Plasmatic levels of CXCL10/IP10, CXCL9/MIG, CCL5/RANTES, and CCL2/MCP‐1 in 14 children, 10 adults with COVID‐19 were measured by Bead Array flow cytometry assay on a single plasma sample at the time of hospital admission, and 10 children with other infections are shown as median ± semi‐interquartile range (pg/ml). Kruskal–Wallis comparison test was used to compare values between healthy control subjects, COVID‐19 children, and adults for analysis of CXCL10/IP10 (NS), CXCL9/MIG (p = 0.0055), CCL5/RANTES (p = 0.0047), and CCL2/MCP‐1 (NS). When the test was statistically significant between three groups, Dunn's multiple comparison test was used for pairwise differences between control group and COVID‐19 children or adults. This was analysis showed significant difference in CXCL9 levels in between COVID‐19 adults and control subjects (p < 0.05), in CCL5 levels between COVID‐19 adults and control subjects (p < 0.05) and between COVID‐19 and control subjects. Nonsignificant (NS) when p > 0.05. Evaluation of T‐cell subsets revealed CD8 lymphopenia in three children with COVID‐19 (P3, P6, P9). None of the adults with COVID‐19 showed CD4 or CD8 lymphopenia. CD4/CD8 ratio, distribution of naïve, central memory, effector memory, and terminally differentiated CD4 and CD8 cells were normal in children as compared to lymphocyte populations of age‐matched subjects analyzed in recent years for unrelated conditions (Supporting information Tables 2 and 3). However, comparison of terminally differentiated CD8 cells between children and adults infected with SARS‐COV‐2 showed a significantly higher number of this subset in adults subjects (data not shown). To investigate whether T detected in children with COVID‐19 was related to impaired lymphocyte generation from thymus and bone marrow, respectively, we measured T‐cell receptor excision circles (TRECs) and, which are considered biomarkers for adequate new T‐cells production. We observed that the levels of TRECs were within the range of age‐matched control subjects in all children with COVID‐19 (data not shown), suggesting that decrease in lymphocyte counts was probably related to lymphocyte apoptosis or to migration of these cells to affected organs such as the lungs. Then, we evaluated the expression of the T‐cell activation marker HLA‐DR in COVID‐19 children and adults as compared to respective age‐matched control groups. We found that the percentage of CD4 and CD8 subsets expressing HLA‐DR was significantly higher in the adults as compared to control subjects, but not in children (Fig. 2, panels A). Additional analyses of HLA‐DR expression by CD4 and CD8 T cells in subjects with dyspnea, including adults (median CD4+/HLA‐DR+: 7.2%; median CD8+/HLA‐DR+: 17.4%) and children (median CD4+/HLA‐DR+: 1.2%; median CD8+/HLA‐DR+: 4.2%), did not show higher activation levels in adults with more severe clinical manifestation as compared with adults (median CD4+/HLA‐DR+: 7.1%; median CD8+/HLA‐DR+: 14.4%) or children (median CD4+/HLA‐DR+: 1.5%; median CD8+/HLA‐DR+: 1.3%) without dyspnea.
Figure 2

Activation marker expression by T cells in COVID‐19 patients. (A) Expression of HLA‐DR+ (%) in CD4 (left panel) and CD8 (right panel) cells in children and adults with COVID‐19 as compared to respective control subjects and analyzed by flow cytometry. Data are shown as median ± semi‐interquartile range (% of cells). HLA‐DR expression was measured on a single blood sample collected at the time of hospital admission. Kruskal–Wallis comparison test was used to compare between healthy control subjects, COVID‐19 children, and adults values of CD4+/HLA‐DR+ cells (p < 0.0001) and of CD8+/HLA‐DR+ cells (p < 0.0001). When the test was statistically significant between three groups, Dunn's multiple comparison test was used for pairwise differences of CD4+/HLA‐DR+ and CD8+/HLA‐DR+ cells between control group and COVID‐19 children or adults. This analysis showed a significant difference in the values of CD4+/HLA‐DR+ and of CD8+/HLA‐DR+ in COVID‐19 adults as compared to control subjects (p < 0.005). (B) Cytokines evaluation in children and adults affected by COVID‐19. Plasmatic levels of IL‐1beta, IL‐12 (p70) in 14 children and 10 adults with COVID‐19 were measured by Bead Array flow cytometry assay on a single plasma sample at the time of hospital admission. Data are shown as mean ± standard deviation (pg/mL). Mann–Whitney comparison test showed significant differences of IL‐1β and IL‐12 values between COVID‐19 children and adults (p < 0.05).

Activation marker expression by T cells in COVID‐19 patients. (A) Expression of HLA‐DR+ (%) in CD4 (left panel) and CD8 (right panel) cells in children and adults with COVID‐19 as compared to respective control subjects and analyzed by flow cytometry. Data are shown as median ± semi‐interquartile range (% of cells). HLA‐DR expression was measured on a single blood sample collected at the time of hospital admission. Kruskal–Wallis comparison test was used to compare between healthy control subjects, COVID‐19 children, and adults values of CD4+/HLA‐DR+ cells (p < 0.0001) and of CD8+/HLA‐DR+ cells (p < 0.0001). When the test was statistically significant between three groups, Dunn's multiple comparison test was used for pairwise differences of CD4+/HLA‐DR+ and CD8+/HLA‐DR+ cells between control group and COVID‐19 children or adults. This analysis showed a significant difference in the values of CD4+/HLA‐DR+ and of CD8+/HLA‐DR+ in COVID‐19 adults as compared to control subjects (p < 0.005). (B) Cytokines evaluation in children and adults affected by COVID‐19. Plasmatic levels of IL‐1beta, IL‐12 (p70) in 14 children and 10 adults with COVID‐19 were measured by Bead Array flow cytometry assay on a single plasma sample at the time of hospital admission. Data are shown as mean ± standard deviation (pg/mL). Mann–Whitney comparison test showed significant differences of IL‐1β and IL‐12 values between COVID‐19 children and adults (p < 0.05). Next, we measured plasmatic levels of cytokines released during inflammatory or immune response including IF‐α (IFN‐α), IF‐γ (IFN‐γ), IL‐1β, IL‐4, IL‐5, IL‐6, IL‐10, IL‐12 (p70), IL‐17A, and TNF‐α. Remarkably, IL‐12 (p70) and IL‐1β were significantly higher in plasma of COVID‐19 children as compared with adults (Fig. 2B). Likewise, IL‐6, IL‐10, and IL‐5 concentrations were higher in plasma of adults with COVID‐19, while IFN‐α was increased in children, but these differences were not statistically significant (data not shown). Concentrations of IL‐4, IL‐17A were below detection levels in both groups of patients (data not shown). It is remarkable that lymphopenia was associated with reduction of CD8 cell counts in some patients, while CD4 counts were normal in all subjects, suggesting that CD8 might be mobilized to lymphoid organs or to the lungs. While adults with COVID‐19, especially severe cases can display persistent lymphopenia [8]. Detection of elevated plasmatic levels of CCL5/RANTES at the early stages of SARS‐Cov‐2 infection suggests its potential role in mobilizing T lymphocytes and monocytes to pulmonary tissues where these chemokines are produced at large amounts. CCL5/RANTES mediates recruitment of T lymphocytes and monocytes; it has also been implicated in arterial injury and in sustaining CD8 T‐cell responses during a viral infection [9]. CCL5/RANTES is produced in large amounts by platelets and activated T cells but it is also expressed by respiratory epithelial cells and has been detected in the lungs of patients with SARS‐COV‐2 infection [7]. HLA‐DR expression on CD4 and CD8 cells was lower in children than in adults with COVID‐19 at the time of hospital admission. One might speculate that activated T cells expressing chemokine receptors for CCL5/RANTES are not detected in peripheral blood because these cells were already mobilized to tissues or that innate immune response might be more effective in children. This is consistent with a recent report describing a moderate increase of CD8+ cells coexpressing HLA‐DR and CD38 during COVID‐19 recovery in one adult patient [10]. Alternatively, SARS‐CoV2 viral load might be more elevated in adult subjects as compared to children resulting in stronger T‐cell activation. In addition, we detected higher levels of IL‐12 (p70) and of CXCL9/MIG in adults with COVID‐19 suggesting that prolonged T‐cell activation in adults with COVID‐19 might result in Th1 polarization and possibly in pulmonary tissue damage by activated T cells.

Conflict of interest

The authors declare no commercial or financial conflict of interest. Supporting Information Click here for additional data file.
  3 in total

1.  Role of CCL5 (RANTES) in viral lung disease.

Authors:  Fiona J Culley; Alasdair M J Pennycook; John S Tregoning; Jonathan S Dodd; Gerhard Walzl; Timothy N Wells; Tracy Hussell; Peter J M Openshaw
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

2.  Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China.

Authors:  Fang Zheng; Chun Liao; Qi-Hong Fan; Hong-Bo Chen; Xue-Gong Zhao; Zhong-Guo Xie; Xi-Lin Li; Chun-Xi Chen; Xiao-Xia Lu; Zhi-Sheng Liu; Wei Lu; Chun-Bao Chen; Rong Jiao; Ai-Ming Zhang; Jin-Tang Wang; Xi-Wei Ding; Yao-Guang Zeng; Li-Ping Cheng; Qing-Feng Huang; Jiang Wu; Xi-Chang Luo; Zhu-Jun Wang; Yan-Yan Zhong; Yan Bai; Xiao-Yan Wu; Run-Ming Jin
Journal:  Curr Med Sci       Date:  2020-03-24

3.  Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19.

Authors:  Irani Thevarajan; Thi H O Nguyen; Marios Koutsakos; Julian Druce; Leon Caly; Carolien E van de Sandt; Xiaoxiao Jia; Suellen Nicholson; Mike Catton; Benjamin Cowie; Steven Y C Tong; Sharon R Lewin; Katherine Kedzierska
Journal:  Nat Med       Date:  2020-04       Impact factor: 87.241

  3 in total
  18 in total

1.  Child mortality in England during the COVID-19 pandemic.

Authors:  David Odd; Sylvia Stoianova; Tom Williams; Vicky Sleap; Peter Blair; Peter Fleming; Ingrid Wolfe; Karen Luyt
Journal:  Arch Dis Child       Date:  2021-06-21       Impact factor: 3.791

2.  SARS-CoV-2-specific T cell memory with common TCRαβ motifs is established in unvaccinated children who seroconvert after infection.

Authors:  Louise C Rowntree; Thi H O Nguyen; Lukasz Kedzierski; Melanie R Neeland; Jan Petersen; Jeremy Chase Crawford; Lilith F Allen; E Bridie Clemens; Brendon Chua; Hayley A McQuilten; Anastasia A Minervina; Mikhail V Pogorelyy; Priyanka Chaurasia; Hyon-Xhi Tan; Adam K Wheatley; Xiaoxiao Jia; Fatima Amanat; Florian Krammer; E Kaitlynn Allen; Sabrina Sonda; Katie L Flanagan; Jaycee Jumarang; Pia S Pannaraj; Paul V Licciardi; Stephen J Kent; Katherine A Bond; Deborah A Williamson; Jamie Rossjohn; Paul G Thomas; Shidan Tosif; Nigel W Crawford; Carolien E van de Sandt; Katherine Kedzierska
Journal:  Immunity       Date:  2022-06-08       Impact factor: 43.474

3.  Natural mucosal barriers and COVID-19 in children.

Authors:  Carl A Pierce; Sharlene Sy; Benjamin Galen; Doctor Y Goldstein; Erika Orner; Marla J Keller; Kevan C Herold; Betsy C Herold
Journal:  JCI Insight       Date:  2021-05-10

4.  Genome-Wide B Cell, CD4+, and CD8+ T Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines.

Authors:  Swayam Prakash; Ruchi Srivastava; Pierre-Gregoire Coulon; Nisha R Dhanushkodi; Aziz A Chentoufi; Delia F Tifrea; Robert A Edwards; Cesar J Figueroa; Sebastian D Schubl; Lanny Hsieh; Michael J Buchmeier; Mohammed Bouziane; Anthony B Nesburn; Baruch D Kuppermann; Lbachir BenMohamed
Journal:  J Immunol       Date:  2021-04-28       Impact factor: 5.426

Review 5.  The cytokine storm and thyroid hormone changes in COVID-19.

Authors:  L Croce; D Gangemi; G Ancona; F Liboà; G Bendotti; L Minelli; L Chiovato
Journal:  J Endocrinol Invest       Date:  2021-02-09       Impact factor: 4.256

6.  Children's role in the COVID-19 pandemic: a systematic review of early surveillance data on susceptibility, severity, and transmissibility.

Authors:  Katy A M Gaythorpe; Sangeeta Bhatia; Tara Mangal; H Juliette T Unwin; Natsuko Imai; Gina Cuomo-Dannenburg; Caroline E Walters; Elita Jauneikaite; Helena Bayley; Mara D Kont; Andria Mousa; Lilith K Whittles; Steven Riley; Neil M Ferguson
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

7.  Case Report: Analysis of Inflammatory Cytokines IL-6, CCL2/MCP1, CCL5/RANTES, CXCL9/MIG, and CXCL10/IP10 in a Cystic Fibrosis Patient Cohort During the First Wave of the COVID-19 Pandemic.

Authors:  Giulia Baresi; Mauro Giacomelli; Daniele Moratto; Marco Chiarini; Immacolata Claudia Conforti; Rita Padoan; Piercarlo Poli; Silviana Timpano; Francesca Caldarale; Raffaele Badolato
Journal:  Front Pediatr       Date:  2021-07-06       Impact factor: 3.418

8.  BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis.

Authors:  Yusuke Tomita; Ryo Sato; Tokunori Ikeda; Takuro Sakagami
Journal:  Vaccine       Date:  2020-08-20       Impact factor: 3.641

9.  Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness.

Authors:  Camilla Tincati; E Stefania Cannizzo; Mauro Giacomelli; Raffaele Badolato; Antonella d'Arminio Monforte; Giulia Marchetti
Journal:  Front Immunol       Date:  2020-10-20       Impact factor: 7.561

Review 10.  Immune response in COVID-19: What do we currently know?

Authors:  Daniela S Oliveira; Nayara I Medeiros; Juliana A S Gomes
Journal:  Microb Pathog       Date:  2020-09-09       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.